ImmuPharma (LON:IMM) Shares Down 17.8% – Here’s What Happened

ImmuPharma plc (LON:IMM) was down 17.8% during mid-day trading on Thursday . The stock traded as low as GBX 3.70 and last traded at GBX 3.70. Approximately 1,186,007 shares traded hands during mid-day trading, a decline of 55% from the average daily volume of 2,650,268 shares. The stock had previously closed at GBX 4.50.

ImmuPharma Stock Down 17.8%

The firm has a fifty day simple moving average of GBX 4.21 and a 200-day simple moving average of GBX 5.30. The company has a market cap of £23.08 million, a PE ratio of -10.00 and a beta of 3.02.

ImmuPharma (LON:IMM) last posted its earnings results on Wednesday, May 27th. The company reported GBX (0.37) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 353.21%. Equities research analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

About ImmuPharma

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.